Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Income from Continuing Operations (2021 - 2025)

Verrica Pharmaceuticals has reported Income from Continuing Operations over the past 5 years, most recently at 8301000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 8301000.0 for Q4 2025, up 38.76% from a year ago — trailing twelve months through Dec 2025 was 18998000.0 (up 74.3% YoY), and the annual figure for FY2025 was 18998000.0, up 74.3%.
  • Income from Continuing Operations for Q4 2025 was 8301000.0 at Verrica Pharmaceuticals, down from 308000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for VRCA hit a ceiling of 1515000.0 in Q3 2022 and a floor of 24752000.0 in Q3 2023.
  • Median Income from Continuing Operations over the past 5 years was 10081500.0 (2022), compared with a mean of 10900950.0.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 111.81% in 2022 and later plummeted 1733.8% in 2023.
  • Verrica Pharmaceuticals' Income from Continuing Operations stood at 9540000.0 in 2021, then surged by 37.89% to 5925000.0 in 2022, then plummeted by 316.02% to 24649000.0 in 2023, then surged by 45.01% to 13554000.0 in 2024, then skyrocketed by 38.76% to 8301000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 8301000.0 (Q4 2025), 308000.0 (Q3 2025), and 393000.0 (Q2 2025) per Business Quant data.